Contrave vs Zepbound: Which Fits Your Weight-Loss Goal?

Contrave vs Zepbound at a Glance

The table below lines up the two drugs on the dimensions that matter most before a prescriber conversation about either one.

How Much Weight Each Drug Actually Removes

Zepbound's headline number comes from the SURMOUNT-1 trial, where participants without diabetes lost 15% to 20.9% of their starting body weight over 72 weeks, depending on dose, against roughly 3% on placebo. That range covers roughly 30 to 45 pounds for someone starting at 220 pounds.

Contrave's trial evidence, at the maximum 32 mg naltrexone/360 mg bupropion dose combined with lifestyle counseling, showed an average of 8.1% total body weight loss over 56 weeks, roughly 18 pounds for the same 220-pound starting point. That is a real, clinically meaningful result on its own, but it lands at roughly a third to a half of what Zepbound's trials show over a similar timeframe.

How Contrave and Zepbound Work Differently

Contrave combines naltrexone, an opioid antagonist normally used to treat alcohol and opioid use disorders, with bupropion, an antidepressant, targeting a specific feedback loop in the hypothalamus. Bupropion stimulates POMC neurons to release alpha-MSH, a signal that reduces food intake and raises energy expenditure. Under normal conditions, those same POMC neurons also release beta-endorphin, which binds opioid receptors and shuts the alpha-MSH signal back off through a negative feedback loop, capping how much appetite suppression bupropion alone can produce. Naltrexone blocks that opioid receptor, preventing the shutoff signal, so the combination produces a larger, more sustained effect than either drug produces on its own, an effect researchers have documented directly as synergistic rather than simply additive. That repurposed-drug combination is also why Contrave carries contraindications tied to each individual ingredient, not just the combination as a whole.

Zepbound mimics two gut hormones, GLP-1 and GIP, that slow stomach emptying, increase satiety after a meal, and improve insulin sensitivity. That dual-hormone mechanism is part of why tirzepatide's trial results run ahead of most other weight-loss drugs, not just Contrave specifically. See our GLP-1 peptides guide for the fuller mechanism behind tirzepatide, semaglutide, and retatrutide.

Who Contrave Rules Out

Contrave's contraindications are more restrictive than Zepbound's, and they trace directly back to its two component drugs. It's contraindicated in anyone with a seizure disorder, since bupropion lowers the seizure threshold in a dose-related way (seizure incidence in Contrave's own trials ran about 0.1%, against 0% on placebo). It's also contraindicated in anyone with a current or prior diagnosis of anorexia nervosa or bulimia, anyone with uncontrolled high blood pressure, and anyone on chronic opioid or opiate-agonist therapy (including methadone or buprenorphine) or going through acute opiate withdrawal, since naltrexone blocks the opioid receptors those treatments depend on. See our Ozempic alternatives comparison for how Contrave stacks up against a wider field of weight-loss options.

Side Effects: Two Different Risk Categories

Contrave's most commonly reported side effects are nausea, constipation, headache, insomnia, and dry mouth, generally most pronounced during the first few weeks of dose escalation. Zepbound's side effects are almost entirely gastrointestinal, nausea, vomiting, diarrhea, and constipation, with rarer but more serious risks including pancreatitis and gallbladder problems. Neither profile is simply worse than the other; Contrave's risks are concentrated in its contraindication list, while Zepbound's are concentrated in its GI tolerability during the early dosing period.

Cost: Contrave Costs Less, but Both Have Assistance Programs

Contrave's retail list price typically runs $530 to $890 a month, though the manufacturer's CurAccess patient support program has offered it for as low as $99 a month with free shipping for eligible patients. Zepbound's list price runs around $1,086 a month, with Eli Lilly's savings card bringing the cost as low as $25 per fill for commercially insured patients who qualify. Even accounting for assistance programs on both sides, Contrave is generally the less expensive option before insurance enters the picture. Our Mounjaro cost guide breaks down the tirzepatide-specific savings-card mechanics in more detail.

The Annual Cost Math, Side by Side

Monthly list prices understate the real gap once you annualize them. Contrave at its full $530 to $890 monthly list price runs $6,360 to $10,680 a year; through the manufacturer's $99/month CurAccess program, that drops to roughly $1,188 a year for eligible patients. Zepbound at its roughly $1,086 monthly list price runs about $13,032 a year; through Eli Lilly's savings card at $25 per fill for eligible commercially insured patients, that drops to $300 a year, though that card requires existing insurance coverage of Zepbound to begin with, unlike Contrave's support program, which applies regardless of insurance status. The practical takeaway: for someone with no insurance coverage for either drug, Contrave's assistance program is the more accessible discount path, since it does not depend on a coverage determination the way Zepbound's savings card does.

Who This Is Not For

Contrave is a poor fit for anyone with a seizure disorder, a history of an eating disorder, uncontrolled hypertension, or any current or recent opioid use, since each of those is an explicit contraindication on its label. Zepbound is a poor fit for anyone who cannot tolerate an injection, has a personal or family history of medullary thyroid carcinoma or MEN2 syndrome, or cannot afford or access coverage for a medication priced above $1,000 a month before assistance.

What Would Change This Answer

A real head-to-head trial directly comparing Contrave and Zepbound, rather than separate trials measured against separate placebo groups, would sharpen this comparison. A meaningful price drop for Zepbound, whether from new manufacturer competition or broader insurance coverage, would also narrow the practical cost gap for anyone currently choosing Contrave mainly on price rather than on its contraindication profile.

Why a Prescriber Might Start With One Over the Other

In practice, the contraindication list often narrows the choice before the weight-loss numbers even enter the conversation. Someone with a history of seizures, an eating disorder, or current opioid therapy for chronic pain has Contrave ruled out on safety grounds regardless of how it compares on results, leaving Zepbound as the more workable option if a GLP-1-class drug fits otherwise. Someone who cannot tolerate needles, has a family history of thyroid cancer, or is priced out of injectable therapy even after the savings card often ends up considering Contrave first for exactly the opposite reason. The efficacy gap between the two matters most for patients who could reasonably take either one, which is a smaller group than either drug's marketing materials suggest.

What to Look For in a Body-Composition Scale

A bioimpedance scale trends body fat and muscle rather than just weight — useful when the number stalls but your composition is improving. The absolute body-fat % isn't lab-accurate, so use it for TRENDS at a consistent time of day. Choose one that syncs to an app so you can watch the trend line.

GE Smart Scale for Body Weight: 8-Electrode Digital Bathroom Scale for Weight Fat BMI Muscle Mass Full Body Composition Analyzer 50 Measurements Bluetooth Highly Accurate Weighing Machine 400lb Black

GE

View on Amazon →

Etekcity Smart Scale for Body Weight, FSA&HSA Eligible, Bathroom Digital Weighing Scale with BMI, Body Fat, Muscle Mass, Accurate Bluetooth Home User Health Equipment Sync Apps, LED, Tempered glass

Etekcity

View on Amazon →